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Abstract Methamphetamine (METH), a commonly
abused psychostimulant, causes dopamine neurotoxicity in
humans, rodents, and nonhuman primates. This study
examined the selective neuroanatomical pattern of dopa-
minergic neurotoxicity induced by METH in the mouse
striatum. We examined the effect of METH on tyrosine
hydroxylase (TH) and dopamine transporter (DAT)
immunoreactivity in the different compartments of the
striatum and in the nucleus accumbens. The levels of
dopamine and its metabolites, 3,4-dihidroxyphenylacetic
acid and homovanillic acid, as well as serotonin (5-HT)
and its metabolite, 5-hydroxyindolacetic acid, were also
quantiﬁed in the striatum. Mice were given three injections
of METH (4 mg/kg, i.p.) at 3 h intervals and sacriﬁced
7 days later. This repeated METH injection induced a
hyperthermic response and a decrease in striatal concen-
trations of dopamine and its metabolites without affecting
5-HT concentrations. In addition, the drug caused a
reduction in TH- and DAT-immunoreactivity when com-
pared to saline-treated animals. Interestingly, there was a
signiﬁcantly greater loss of TH- and DAT-immunoreac-
tivity in striosomes than in the matrix. The predominant
loss of dopaminergic terminals in the striosomes occurred
along the rostrocaudal axis of the striatum. In contrast,
METH did not decrease TH- or DAT-immunoreactivity in
the nucleus accumbens. These results provide the ﬁrst
evidence that compartments of the mouse striatum, strio-
somes and matrix, and mesolimbic and nigrostriatal path-
ways have different vulnerability to METH. This pattern is
similar to that observed with other neurotoxins such as
MPTP, the most widely used model of Parkinson’s disease,
in early Huntington’s disease and hypoxic/ischemic injury,
suggesting that these conditions might share mechanisms
of neurotoxicity.
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Abbreviations
METH Methamphetamine
PB Phosphate buffer
PBST Phosphate sodium buffer with Triton X-100
DA Dopamine
TH Tyrosine hydroxylase
DAT Dopamine transporter
MOR-I Opioid l receptor
DOPAC 3,4-Dihidroxyphenylacetic acid
HVA Homovanillic acid
5-HT Serotonin
5-HIAA 5-Hydroxyindolacetic acid
MDMA 3,4-Methylenedioxymethamphetamine
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
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Methamphetamine (METH) is an illicit psychostimulant
that is widely abused. The United Nations Ofﬁce on Drugs
and Crime (UNODC) conservatively estimates that there
are between 15 and 16 million METH users worldwide, a
ﬁgure similar to those for heroin and cocaine (UNODC
2008). The immediate effects of METH are associated with
an increase in serotonin (5-HT) and dopamine (DA) con-
centrations in the synaptic cleft. METH exposure causes
long-term neurotoxicity in rodents, nonhuman primates,
and humans, and although some serotonergic loss is
reported, mainly in rats (Wagner et al. 1980; Green et al.
1992; Nowak et al. 2007; Bortolato et al. 2009; Cadet et al.
2009), it predominantly affects the dopaminergic system
(Seiden et al. 1976; Wagner et al. 1980; McCann et al.
1998; Melega et al. 2000; Cadet et al. 2007; Daberkow
et al. 2008; Krasnova and Cadet 2009). In mice, repeated
administration of METH produces neurodegeneration of
dopamine axon terminals in the striatum and cell body loss
in the substantia nigra (Sonsalla et al. 1996; Hirata and
Cadet 1997). Damage has been demonstrated both histo-
logically (O’Callaghan and Miller 1994) and biochemically
(Sonsalla et al. 1989; Mann et al. 1997; Itzhak et al. 2000;
Hogan et al. 2000; Staal et al. 2000; Nowak et al. 2007) and
is reﬂected as a substantial decrease in the concentration of
dopamine and its metabolites, a loss in the density of
plasmalemmal and vesicular dopamine transporters, and a
decrease in tyrosine hydroxylase (TH) activity. The
mechanisms underlying this neurodegeneration are not
fully understood currently, but a considerable body of data
indicates that reactive oxygen and nitrogen species play an
essential role (Itzhak et al. 1998, 2000; Deng and Cadet
1999; Imam et al. 2001; Krasnova and Cadet 2009).
We have recently found that the dopaminergic terminal
loss induced in the striatum by MDMA, another amphet-
amine derivative compound, occurs predominantly in the
striosomes compared to the matrix (Granado et al. 2008a).
Interestingly, this pattern of dopaminergic terminal
neurotoxicity is similar to that shown in early stages of
MPTP-induced neurotoxicity in monkeys (Iravani et al.
2006) and in the adult weaver mouse (Graybiel et al. 1990).
A predominant loss of TH in the striosomes has also been
shown in a transgenic mouse model of dopa-responsive
dystonia (Sato et al. 2008). Remarkably, this pattern not
only applies to dopaminergic terminals but also extends to
medium spiny neurons within the striosomal compartment,
as found in early stages of Huntington disease (Hedreen
and Folstein 1995) and after forebrain hypoxic-ischemic
injury (Burke and Baimbridge 1993). Interestingly, these
neurons are dopaminoceptive: they are innervated by
dopaminergic terminals and express D1 or D2 dopamine
receptors.
The striosome/matrix cytoarchitectonic organization of
the striatum plays a central role in the functional organi-
zation of the striatum. Because of their connections with
the limbic system, striosomes are functionally associated
with reward-related behaviors (White and Hiroi 1998) and
stimulant-induced neuronal events (Moratalla et al. 1996).
The matrix is connected to sensorimotor regions of the
brain and is more closely associated with normal motor
functions (Berretta et al. 1997; Brown et al. 2002). Given
the functional importance of the striosomes/matrix orga-
nization, an imbalance in the physiological dopaminergic
activity or in differential signaling efﬁcacy between these
two compartments has been associated with the patho-
genesis of abnormal and persistent motor behaviors and
pathological reinforcement induced by repetitive adminis-
tration of dopaminergic drugs (Moratalla et al. 1996; Hiroi
et al. 2002; Sato et al. 2008; Crittenden et al. 2009;
Darmopil et al. 2009).
To investigate whether the differential vulnerability of
these two compartments to METH toxicity underlies the
pathological consequences of METH abuse, we studied the
relative susceptibility of the striatal compartments to
the neurotoxic effects of METH by evaluating changes in
the expression of two dopaminergic nigrostriatal markers,
TH and dopamine transporter (DAT), 7 days after repeated
METH administration. Our results show that striosomes are
more vulnerable to METH than matrix.
Experimental Procedures
Animals and Treatment
Adult female C57BL/6J mice (20–25 g, Harlan Iberica,
Barcelona, Spain) were housed in groups of 4–6 per cage at
the Instituto Cajal in conditions of constant temperature at
21 ± 2C, in a 12 h light/dark cycle, with free access to
food and water. All experimental procedures were
approved by the Bioethics Committee of the Instituto Cajal
(following DC86/609/EU).
Mice received three injections of METH (4 mg/kg, i.p.)
with 3 h intervals between injections. Control mice were
given saline. Doses are expressed as free base. METH was
obtained from Sigma-Aldrich (Madrid, Spain).
Measurement of Rectal Temperature
Rectal temperature was measured using a digital readout
thermocouple (BAT-12 thermometer, Physitemp Instru-
ments, Clifton, NJ, USA) with a resolution of 0.1C and
accuracyof±0.1CattachedtoaRET-3RodentSensor.The
sensor was inserted 2 cm into the mouse rectum while the
mousewaslightlyrestrainedbyholdinginthehand.Asteady
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123readout was obtained within 10 s of probe insertion. Tem-
perature readings were taken every 30 min immediately
before and after METH injections and hourly thereafter.
Immunohistochemistry
Seven days after the administration of METH (4 mg/kg, i.p.
39), animals were deeply anesthetized (50 mg/kg, sodium
pentobarbital) and transcardially perfused with 4% parafor-
maldehyde. Immunostaining was carried out in free-ﬂoating
brain sections (30 lm) with standard avidin–biotin immu-
nohistochemical protocols (Granado et al. 2008b, c; Martı ´n
et al. 2008; Rodrigues et al. 2007), with speciﬁc TH antisera
(1:1,000; Chemicon International, Temecula, CA, USA),
DAT monoclonal antibody (1:5,000; Chemicon Interna-
tional), and a l opioid receptor (MOR-1) antisera (1:10,000;
Chemicon International). After incubation with the primary
(overnight) and secondary antisera (1 h; Vector Laborato-
ries), peroxidase reactions were developed in diaminobenzi
dine.
Quantiﬁcation of TH and DAT striatal expression was
performed with the aid of an image analysis system (AIS,
Imaging Research Inc., Linton, England) using a 59 lens.
The proportional TH- or DAT-stained area was determined
in each visible striosome and in its surrounding matrix,
through the rostrocaudal axis of the striatum (Granado
et al. 2008a, b). The data are presented as the proportional
stained area (total TH- or DAT-positive area/scan area) in
the striatal compartments in control and METH-treated
animals. Measurements were carried out in ﬁve animals per
treatment (5–6 sections/animal). The proportional TH- or
DAT-immunostained area in the whole striatum was also
measured (Granado et al. 2008b).
Measurement of Monoamines and Metabolites in
Striatum
Seven days after treatment, the mice were killed by cer-
vical dislocation, the brains were rapidly removed, and the
striatum dissected out on ice. Dopamine, serotonin, and the
metabolites—3,4-dihydroxyphenylacetic acid (DOPAC),
homovanillic acid (HVA), and 5-hydroxyindolacetic acid
(5-HIAA)—were measured by high-performance liquid
chromatography and electrochemical detection. The mobile
phase consisted of KH2PO4 (0.05 M), octanesulfonic acid
(0.4 mM), EDTA (0.1 mM), and methanol (16%) and was
adjusted to pH 3 with phosphoric acid, ﬁltered, and
degassed. The ﬂow rate was 1 ml/min. The high-perfor-
mance liquid chromatography system consisted of a pump
(Waters 510) linked to an automatic sample injector (Loop
200 ll, Waters 717 plus Autosampler) and a stainless steel
reversed-phase column (Spherisorb ODS2, 5 lm, 150 9
4.6 mm
2; Waters, Milford, MA, USA) with a pre-column
andacoulometricdetector(CoulochemII;Esa,Chelmsford,
MA, USA). The working electrode potential was set at
400 mVwithagainof1 lA(fordopamine)and500 nA(for
the remaining compounds). The current produced was
monitored by means of integration software (Unipoint;
Gilson, Villier Le Bel, France).
Statistics
Data are presented as mean ± standard error of the mean
(S.E.M.). The results of rectal temperature measurements
were analyzed using one-way analysis of variance
(ANOVA) for repeated measures.
Data obtained from image analysis of striatal TH and
DAT immunostaining were analyzed using one-way
ANOVA. Relevant differences were analyzed pairwise by
post hoc comparisons with Tukey’s test or Dunn’s test to
determine speciﬁc group differences. P values less than
0.05 were considered statistically signiﬁcant.
All statistical analyses were performed using SigmaStat
2.03 program, and graphical representations were obtained
using SigmaPlot 9.0 software.
Results
METH Induces Hyperthermia
METHtreatment(4 mg/kg,i.p.,threeinjectionsgivenat3 h
intervals) resulted in signiﬁcant changes in rectal tempera-
tures(Fig. 1).TheﬁrstinjectionofMETHinducedamarked
hypothermic response (1.2C below that of saline-treated
Fig. 1 Effect of METH on mouse rectal temperature. Repeated
METH administration (4 mg/kg, i.p., every 3 h, 39) produced a
decrease in rectal temperature of the animals after the ﬁrst injection
and an increase in the rectal temperature, peaking 30 min after the
second and third injections. The arrows indicate the time of drug
injection. Data represent mean ± S.E.M., n = 6 animals/group
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123mice),peakingat30 minandlastingatleast1 h.Thesecond
and third injections caused transient hyperthermia (1–1.5C
above saline) which reached a peak 30 min after each
injection. The highest value was reached after the second
injection of METH reaching 39.2C. Statistical comparison
revealed a signiﬁcant difference between the response of
micetoMETHandtosalinewithintheﬁrst60 minfollowing
the ﬁrst, second, and third injections (P\0.001 as by one-
way ANOVA RM) (Fig. 1).
METH-Induced TH Loss in Mouse Striatum
Seven days after METH administration, immunohisto-
chemistry revealed a marked overall decrease in density of
TH-immunoreactive ﬁbers in the striatum (Fig. 2) com-
pared to the intense TH staining in saline-treated animals
(Fig. 2a–f). Furthermore, in the caudoputamen of animals
treated with METH, we saw patches or pockets with severe
loss of TH-positive ﬁbers compared with the rest of stria-
tum. Although the TH ﬁber loss was similar along the
rostrocaudal axis of the caudoputamen, we observed a
signiﬁcantly greater loss in the lateral part (Fig. 2d–f),
suggesting that the motor areas are more vulnerable to
METH than associative or limbic areas of the striatum.
Quantitative image analysis revealed a signiﬁcant decrease
of 37.3% in TH-ir ﬁbers within the caudoputamen of
drug-treated animals 7 days after METH administration
compared to saline-treated controls (P\0.001) (Fig. 2g).
DAT Loss in the Striatum of METH-Treated Mice
To conﬁrm that TH ﬁber loss reﬂected terminal damage and
not just a reduction in TH synthesis, we used immunohis-
tochemistry to evaluate the expression of dopamine trans-
porter (DAT). DAT is located on dopaminergic terminals
and is expressed independently of TH synthesis or accu-
mulation. METH also produced a signiﬁcant loss of striatal
DAT-positive ﬁbers 7 days after injection compared with
saline-treated mice (Fig. 3). As expected, the pattern of
DAT-ir loss paralleled the pattern of TH-ir loss, with a
similardecreaseinDAT-irﬁbersalongtherostrocaudalaxis,
and a greater loss of DAT-ir ﬁbers in striosomes and in the
lateral striatum (Fig. 3a–f). Quantiﬁcation of DAT-ir by
image analysis revealed a signiﬁcant decrease of 67% in
METH-treated mice compared to saline-treated animals
(P\0.001) (Fig. 3g).
Striosomes Are More Vulnerable to METH
Neurotoxicity Than Matrix
Interestingly, in METH-treated animals, we also found that
TH- and DAT-ir loss was greater in patches than in the rest
Fig. 2 Effect of METH on TH-immunoreactivity in the striatum.
Photomicrographs of striatal sections from mice treated with saline
(a–c) or METH (d–f) stained for TH. Animals were killed 7 days
after treatment. Note the TH-ir loss in the METH-treated mice along
the rostrocaudal axis of the striatum. (g) Histograms of the
proportional stained area of TH-ir. METH (4 mg/kg, i.p., every 3 h,
39) produced a reduction in TH-immunoreactivity levels. Data
represent mean ± S.E.M., n = 6 animals/group. * P\0.001 vs.
saline, one-way ANOVA. Bar 500 lm
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123of striatum (Fig. 4). To determine if these patches of highly
damaged striatum corresponded to the location of strio-
somes, we performed immunostaining for MOR-1, a stri-
osomal marker, in sections adjacent to those stained with
TH or DAT. Areas immunostained with MOR-1 corre-
sponded in number, size, and shape to the patches of
greatest TH and DAT ﬁber loss (Fig. 4a–c). In the most
damaged striatal areas, like the lateral part, this striosome/
Fig. 3 METH produces a decrease in DAT-immunoreactivity in the
striatum. Photomicrographs of striatal sections from mice sacriﬁced
7 days after treatment with saline (a–c) or METH (d–f) stained for
DAT. Note the DAT-ir loss in the METH-treated mice along the
rostrocaudal axis of the striatum. (g) Histograms show the
proportional stained area of DAT-immunoreactivity. METH (4 mg/kg,
i.p., every 3 h, 39) produced a reduction in DAT-immunoreactivity
levels. Data represent mean ± S.E.M., n = 6 animals/group;
* P\0.001 vs. saline, one-way ANOVA. Bar 500 lm
Fig. 4 TH- and DAT-ir loss
occurs predominantly in
striosomes. Serially adjacent
sections from a mouse treated
with METH were stained for
TH (a), MOR-1 (b), and DAT
(c). Most patches of weak TH-ir
matched patches of weak DAT-
ir and both areas corresponded
with striosomes identiﬁed by
MOR-1 immunostaining. a0–c0
show an example of a striosome
at higher magniﬁcation. Bar
500 lm( a–c) and 200 lm
(a0–c0)
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123matrix pattern in TH/DAT staining was no longer evident
due to the greater TH and DAT loss in these areas.
To study the relative vulnerability of striosomes com-
pared to the matrix, we quantiﬁed TH-ir in both striatal
compartments: striosomes and matrix (Fig. 5). When we
determined the proportional area stained by TH, we found
signiﬁcant differences between the METH- and saline-
treated animals for both the striosomes and matrix in
medial, central, and lateral areas of the striatum. We also
found that the difference was greater for the striosomes
(average 88%, P\0.001) than for the matrix (average
53%, P\0.01) in all areas; however, the difference in TH
content between striosomes and matrix was greatest in the
medial area and lowest in the lateral area. It should be
noted that in METH-treated mice, there was greater overall
damage in the lateral striatum compared to the medial and
central matrix of striatum (P\0.05, respectively) (Fig. 5).
Similar data were obtained when DAT-ir quantiﬁcations
were performed (data not shown).
Striatal Dopamine and 5-HT Concentrations
in METH-Treated Mice
Seven days after METH administration (4 mg/kg, three
times at 3 h intervals), there was a reduction (76%) in the
striatal dopamine content (ng/g tissue) of METH-treated
mice compared to saline (P\0.001). The metabolites of
dopamine, DOPAC and HVA, were also affected by
treatment with METH. DOPAC was reduced by 64%
(P\0.001) and HVA levels by 59% (P\0.001) in the
METH-treated mice (Fig. 6). There were no differences
between METH- and saline-treated animals in striatal 5-HT
concentration or 5-HIAA concentration (P = 0.67 and
P = 0.63, respectively) (Fig. 6).
METH Administration Does Not Affect TH-ir
in the Nucleus Accumbens
In contrast to our ﬁnding that administration of METH
produces a marked loss of TH and DAT ﬁbers in the stri-
atum, we found no change in TH- or DAT-ir in the nucleus
accumbens (NAc) (Fig. 7). Quantitative image analysis
revealed no signiﬁcant difference in TH-ir in the NAc
between METH- and saline-treated mice 7 days after
METH administration (P = 0.12) (Fig. 7c). These studies
demonstrate that METH selectively reduces dopaminergic
terminals in the striatum, but not in the NAc.
Discussion
Previous studies have shown that acute administration of
repeated doses of METH to mice induces a long-term
neurotoxic effect reﬂected by selective loss of nigrostriatal
dopamine markers. The overall aim of this study was to
investigate whether the striosome and matrix compart-
ments of the mouse striatum show differential vulnerability
to METH as evidenced by differences in TH- and DAT-
immunostaining. This study provides the ﬁrst evidence that
METH produces a greater loss of TH/DAT positive ter-
minals in the striosomes than in the matrix, suggesting that
the striosomes are differentially affected by METH. Fur-
thermore, under our experimental conditions, METH pro-
duces no toxicity in the mesolimbic dopaminergic pathway.
Levels of TH- and DAT-immunoreactivity are com-
monly used indexes of dopaminergic terminal damage
(Iravani et al. 2005; Pavo ´n et al. 2006; Granado et al.
2008a, b; Darmopil et al. 2008, 2009), and decreased TH
levels have been reported after treatment with dopami-
nergic neurotoxins including METH, MDMA, 6-OHDA,
and MPTP (Moratalla et al. 1992; Fornai et al. 2004;
Broening et al. 2005; Iravani et al. 2005; Pavo ´n et al. 2006;
Thomas et al. 2009). In this study, we have demonstrated a
marked loss of TH expression in the striosomes of mice
treated with METH. In addition, this decrease in TH
expression is accompanied by a reduction in DAT, an
important marker of functional dopaminergic nerve ter-
minals. The decrease in DAT expression indicates that the
decreased TH-ir is not due to a decrease in TH synthesis
but rather due to neuronal damage of dopaminergic ter-
minals. This is further supported by the reduction in the
concentration of dopamine and its principle metabolites in
the striatum of METH-treated mice.
Fig. 5 Loss of TH-immunoreactivity is greater in striosomes than in
the matrix compartment. Histograms represent the proportional
stained area of TH-immunoreactivity in striosomes (stm) and matrix
(mtx) in the medial, center, and lateral areas of the striatum. Striatal
slices from mice treated with METH (three injections of 4 mg/kg i.p.
at 3 h intervals) were compared with those from saline-treated
animals. * P\0.001 vs. saline;
# P\0.01 vs. matrix;
& P\0.05
vs. lateral matrix
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eration of dopaminergic nerve terminals is not known, a
substantial body of evidence indicates that oxygen and
nitrogen reactive species play an essential role. A single
injection of METH induces a rapid increase in 2,3-DHBA
in the striatal dialysate lasting for at least 2 h, a clear
indication that hydroxyl radicals are being formed (Bat-
taglia et al. 2002). Oxygen reactive species could come
from auto-oxidation of extravesicular dopamine producing
hydrogen peroxide (H2O2) which forms hydroxyl radicals
and superoxide anion (O2
-) (Simola et al. 2007). These
species could, in turn, react with NO to generate the
potent oxidant peroxynitrite (ONOO
-) and other reactive
oxygen radicals (Beckman 1991; Radi et al. 1991).
METH increases 3-nitrotyrosine levels in mouse striatum,
an index for ONOO
- production, and this effect is absent
in nNOS knockout mice or mice overexpressing Cu/Zn
superoxide dismutase (SOD) (Imam et al. 2001). In
addition, nNOS inhibitors completely prevent the loss of
dopamine induced by METH (Itzhak et al. 2000; Sanchez
et al. 2003), and the neurotoxic effects of METH in the
striatum are attenuated in transgenic mice overexpressing
Cu/Zn-SOD (Cadet et al. 1994; Hirata et al. 1996). The
latter results are particularly relevant since SOD is more
abundant in the matrix than in the striosomes (Medina
et al. 1996; Zhang et al. 1994) and this distribution
Fig. 6 Effect of METH on the
striatal content of DA, DOPAC,
and HVA. Amine levels were
measured by HPLC in
homogenates from striata of
mice treated with METH (4 mg/
kg) or saline. Mice were
sacriﬁced 7 days after drug
administration. Data represent
the mean ± SEM, n = 6
animals/group. * 0.001
compared with control animals
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123pattern tightly corresponds with the relative preservation
of TH- and DAT-ir in the matrix following METH.
Therefore, it seems reasonable to propose that the
increased susceptibility of the striosomal compartment to
the damaging effects of METH may be related to a lower
antioxidant capacity in striosomes than in matrix. It is
likely that at higher doses of METH, the differential vul-
nerability between striosomes and matrix that we report
here might be lost since the higher METH dose would
overwhelm the protective capacities of both compartments.
A similar pattern of greater striosomal damage in the
striatum has been observed following the administration of
other neurotoxins such as MDMA (Granado et al. 2008a, b)
and MPTP (Iravani et al. 2005), or NMDA receptor ago-
nists such as quinolinic acid (Figueredo-Cardenas et al.
1998). It is also seen in early Huntington’s disease
(Hedreen and Folstein 1995) and following ischemia/
reperfusion injury (Burke and Baimbridge 1993; Medina
et al. 1996). Given the role of free radicals in cell damage
(Fiskum et al. 1999), the difference in SOD levels between
the striatal compartments may offer at least a partial
explanation for the differential vulnerability observed in all
these conditions. It suggests that common mechanisms may
underlie the cell damage caused by these different neuro-
toxins and neurodegenerative diseases.
On the other hand, METH increases the extracellular
concentration of glutamate in striatum (Nash and
Yamamoto 1992; Stephans and Yamamoto 1994), and
glutamate is involved in mediating the neurotoxic effects of
METH by overactivating N-methyl-D-aspartate (NMDA)
and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propi-
onic acid (AMPA) receptors, causing excitotoxicity. In fact,
NMDA receptor antagonists block the long-term dopamine
loss induced by METH (Fuller et al. 1992; Layer et al. 1993;
Ohmori et al. 1993; Thomas and Kuhn 2005; Ke et al.
2008). AMPA and NMDA glutamate receptors have dif-
ferential distribution in the striatal compartments. AMPA
receptors containing GluR1 may predominate in striosomes,
while AMPA receptors with GluR4 are more abundant in
the matrix (Martin et al. 1993). NMDA receptors also
appear to predominate in striosomes as suggested by in vitro
studies showing that NMDA had a greater stimulatory
effect on the release of dopamine in the striosomes than in
matrix compartment (Gauchy et al. 1996). Thus, striosomes
and matrix appear to express different glutamate receptors
or receptor subunit combinations which could have conse-
quences relevant to the neuropathology induced by METH.
The idea that differences in glutamate receptor activation
play a role in the degree of neurotoxicity in different striatal
compartments is supported by reports that calbindin
expression is associated with relative resistance to MPTP
damage since high intracellular levels of calcium binding
protein may protect the cell against excessive calcium entry
(Burke and Baimbridge 1993). Interestingly, the calbindin
distribution pattern in the striatum corresponds with the
pattern of relative protection against METH-induced
dopaminergic loss in the matrix.
In conclusion, this study indicates that in mice METH
produces greater damage to the dopaminergic nerve ter-
minals in the striosomes than to those in the matrix, where
the mesolimbic dopaminergic pathway is relatively pre-
served. The neurotoxicity which leads to this greater
vulnerability of the striosomes and the nigrostriatal dopa-
minergic pathway may involve factors that are common to
other types of neuronal injury such as those produced by
ischemia, excitotoxicity, MPTP, or HD. Further studies are
necessary to evaluate the precise mechanisms involved in
this drug-induced cell damage and to determine why
striosomes are uniquely sensitive to METH and to other
neurodegenerative diseases.
Fig. 7 The NAc does not exhibit METH-induced neurotoxicity.
Photomicrographs of TH-immunoreactivity in the NAc of mice
treated with saline (a) or METH (b). Animals were killed 7 days after
treatment. c Histograms of the proportional stained area of
TH-immunoreactivity. METH (4 mg/kg, i.p., every 3 h, 39) pro-
duced no reduction in TH-immunoreactivity. Data represent
mean ± S.E.M., P = 0.12; n = 6 animals/group. Bar 500 lm
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